Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • RSLV-145
    • RSLV-621
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Unmet Medical Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • RSLV-145
    • RSLV-621
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Unmet Medical Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

Daily Archives: December 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

NewsBy James PosadaDecember 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

Improvement of Severe Fatigue Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

PublicationsBy James PosadaDecember 8, 2020

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

NewsBy James PosadaDecember 8, 2020

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top